Global Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030

Global Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030


Summary

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

According to APO Research, The global Biologics and Biosimilars market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Biologics and Biosimilars segment by Company

Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Biologics and Biosimilars segment by Type

Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Biologics and Biosimilars segment by Application

Tumor
Diabetes
Cardiovascular
Hemophilia
Others
Biologics and Biosimilars segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report


1 Market Overview
1.1 Product Definition
1.2 Global Biologics and Biosimilars Market Size, 2019 VS 2023 VS 2030
1.3 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2019-2030)
1.4 Global Biologics and Biosimilars Sales Estimates and Forecasts (2019-2030)
1.5 Global Biologics and Biosimilars Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Biologics and Biosimilars Market Dynamics
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 Biologics and Biosimilars Market by Manufacturers
3.1 Global Biologics and Biosimilars Revenue by Manufacturers (2019-2024)
3.2 Global Biologics and Biosimilars Sales by Manufacturers (2019-2024)
3.3 Global Biologics and Biosimilars Average Sales Price by Manufacturers (2019-2024)
3.4 Global Biologics and Biosimilars Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
3.7 Global Biologics and Biosimilars Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
3.8.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
4 Biologics and Biosimilars Market by Type
4.1 Biologics and Biosimilars Type Introduction
4.1.1 Monoclonal Antibodies
4.1.2 Interferon
4.1.3 Erythropoietin
4.1.4 Insulin
4.1.5 Vaccines
4.1.6 Others
4.2 Global Biologics and Biosimilars Sales by Type
4.2.1 Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Biologics and Biosimilars Sales by Type (2019-2030)
4.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
4.3 Global Biologics and Biosimilars Revenue by Type
4.3.1 Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Biologics and Biosimilars Revenue by Type (2019-2030)
4.3.3 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
5 Biologics and Biosimilars Market by Application
5.1 Biologics and Biosimilars Application Introduction
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.4 Hemophilia
5.1.5 Others
5.2 Global Biologics and Biosimilars Sales by Application
5.2.1 Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Biologics and Biosimilars Sales by Application (2019-2030)
5.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
5.3 Global Biologics and Biosimilars Revenue by Application
5.3.1 Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Biologics and Biosimilars Revenue by Application (2019-2030)
5.3.3 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
6 Global Biologics and Biosimilars Sales by Region
6.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Biologics and Biosimilars Sales by Region (2019-2030)
6.2.1 Global Biologics and Biosimilars Sales by Region (2019-2024)
6.2.2 Global Biologics and Biosimilars Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Biologics and Biosimilars Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Biologics and Biosimilars Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Biologics and Biosimilars Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Biologics and Biosimilars Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 Global Biologics and Biosimilars Revenue by Region
7.1 Global Biologics and Biosimilars Revenue by Region
7.1.1 Global Biologics and Biosimilars Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Biologics and Biosimilars Revenue by Region (2019-2024)
7.1.3 Global Biologics and Biosimilars Revenue by Region (2025-2030)
7.1.4 Global Biologics and Biosimilars Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Biologics and Biosimilars Revenue (2019-2030)
7.2.2 North America Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Biologics and Biosimilars Revenue (2019-2030)
7.3.2 Europe Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Biologics and Biosimilars Revenue (2019-2030)
7.4.2 Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Biologics and Biosimilars Revenue (2019-2030)
7.5.2 LAMEA Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
8 Company Profiles
8.1 Roche
8.1.1 Roche Comapny Information
8.1.2 Roche Business Overview
8.1.3 Roche Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 Roche Biologics and Biosimilars Product Portfolio
8.1.5 Roche Recent Developments
8.2 Amgen
8.2.1 Amgen Comapny Information
8.2.2 Amgen Business Overview
8.2.3 Amgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 Amgen Biologics and Biosimilars Product Portfolio
8.2.5 Amgen Recent Developments
8.3 AbbVie
8.3.1 AbbVie Comapny Information
8.3.2 AbbVie Business Overview
8.3.3 AbbVie Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
8.3.5 AbbVie Recent Developments
8.4 Sanofi-Aventis
8.4.1 Sanofi-Aventis Comapny Information
8.4.2 Sanofi-Aventis Business Overview
8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
8.4.5 Sanofi-Aventis Recent Developments
8.5 Johnson & Johnson
8.5.1 Johnson & Johnson Comapny Information
8.5.2 Johnson & Johnson Business Overview
8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
8.5.5 Johnson & Johnson Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Novo Nordisk
8.7.1 Novo Nordisk Comapny Information
8.7.2 Novo Nordisk Business Overview
8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
8.7.5 Novo Nordisk Recent Developments
8.8 Eli Lilly
8.8.1 Eli Lilly Comapny Information
8.8.2 Eli Lilly Business Overview
8.8.3 Eli Lilly Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
8.8.5 Eli Lilly Recent Developments
8.9 Novartis
8.9.1 Novartis Comapny Information
8.9.2 Novartis Business Overview
8.9.3 Novartis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.9.4 Novartis Biologics and Biosimilars Product Portfolio
8.9.5 Novartis Recent Developments
8.10 Merck
8.10.1 Merck Comapny Information
8.10.2 Merck Business Overview
8.10.3 Merck Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.10.4 Merck Biologics and Biosimilars Product Portfolio
8.10.5 Merck Recent Developments
8.11 3sbio
8.11.1 3sbio Comapny Information
8.11.2 3sbio Business Overview
8.11.3 3sbio Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.11.4 3sbio Biologics and Biosimilars Product Portfolio
8.11.5 3sbio Recent Developments
8.12 Changchun High Tech
8.12.1 Changchun High Tech Comapny Information
8.12.2 Changchun High Tech Business Overview
8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
8.12.5 Changchun High Tech Recent Developments
8.13 CP Guojian
8.13.1 CP Guojian Comapny Information
8.13.2 CP Guojian Business Overview
8.13.3 CP Guojian Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
8.13.5 CP Guojian Recent Developments
8.14 Biotech
8.14.1 Biotech Comapny Information
8.14.2 Biotech Business Overview
8.14.3 Biotech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.14.4 Biotech Biologics and Biosimilars Product Portfolio
8.14.5 Biotech Recent Developments
8.15 Gelgen
8.15.1 Gelgen Comapny Information
8.15.2 Gelgen Business Overview
8.15.3 Gelgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
8.15.5 Gelgen Recent Developments
8.16 Innovent
8.16.1 Innovent Comapny Information
8.16.2 Innovent Business Overview
8.16.3 Innovent Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.16.4 Innovent Biologics and Biosimilars Product Portfolio
8.16.5 Innovent Recent Developments
8.17 Dong Bao
8.17.1 Dong Bao Comapny Information
8.17.2 Dong Bao Business Overview
8.17.3 Dong Bao Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
8.17.5 Dong Bao Recent Developments
8.18 Ganlee
8.18.1 Ganlee Comapny Information
8.18.2 Ganlee Business Overview
8.18.3 Ganlee Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.18.4 Ganlee Biologics and Biosimilars Product Portfolio
8.18.5 Ganlee Recent Developments
8.19 United Laboratories
8.19.1 United Laboratories Comapny Information
8.19.2 United Laboratories Business Overview
8.19.3 United Laboratories Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
8.19.5 United Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Biologics and Biosimilars Value Chain Analysis
9.1.1 Biologics and Biosimilars Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biologics and Biosimilars Production Mode & Process
9.2 Biologics and Biosimilars Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biologics and Biosimilars Distributors
9.2.3 Biologics and Biosimilars Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings